The Chinatown Walgreens Rejection

The line at the Walgreens pharmacy counter—the one on the edge of Chinatown in San Francisco—moves at the speed of bureaucracy.

Fluorescent lights hum overhead, and people shuffle forward, clutching paper bags and plastic prescription bottles. I do light stretches with others as we wait in line.

When it is finally my turn at the window, the clerk stares at her terminal, types furiously, and gives me the same rehearsed and sympathetic grimace I've heard before: Denied. 

My authorization for Ozempic was rejected. That means my insurance company refused to help cover the cost.

I am a 73-year-old man trying to preserve my cardiovascular health, keep visceral fat off my organs, dampen systemic inflammation, and buy myself an extra two decades of vital life. 

Full disclosure, I am lucky to be able to afford rackrate meds when most people cannot.

It’s tempting to blame a faceless insurance algorithm. But under the denial lies a healthcare apparatus that impedes healthy longevity.

And nurses, doctors and other medical professionals should receive a standing ovation for navigating this broken system every day.

Semaglutide (i.e., Ozempic) is a synthetic peptide drug from Novo Nordisk. It mimics GLP-1, a gut hormone that slows stomach emptying, signals fullness to the brain, and promotes insulin release to manage blood sugar. Bottom line: you eat and drink less.

Because of its positive effects on weight and diabetes, the FDA has approved it to treat people with metabolic conditions. However, emerging research suggests that it also behaves like a longevity therapeutic. 

Whether it's tamping down systemic inflammation, clearing visceral fat, easing vascular strain, or restoring metabolic flexibility, GLP-1s appear to target pillars of biological aging.

However, the FDA does not recognize aging as an actionable condition to treat. This feels like medical bureaucratic inertia compromising healthy longevity.

In the meantime, Novo Nordisk has had to spend hundreds of millions playing regulatory charades, slicing a single mechanism into disease-specific billing codes:

The result may be a warped healthcare market, one where insurers pay top dollar when you suffer from a diagnosed disease, but not to prevent it.

Doctors must wait until patients are sick enough to qualify for insurance. Only when the patient has a disease can they receive financial help to cover the cost of a drug. 

Everyone else is shoved into a booming gray market of compounding pharmacies, telehealth runarounds, and $1,000-a-month out-of-pocket pill bills. I’ve known some to beat a path to Mexico to find the drugs cheaper, or order knock-offs online.

Another example is metformin, a 10-cent pill with decades of observational and preclinical data pointing to broad longevity benefits. 

Dr. Nir Barzilai has spent over a decade fighting to get the TAME (Targeting Aging with Metformin) trial off the ground. The mission was to study the compound, since it’s the only way to force the FDA to evaluate a drug designed explicitly to delay the diseases of aging.

The agency still refuses to recognize these biomarkers as legitimate reasons to access affordable drugs.

So, to satisfy regulators, Barzilai had to invent an administrative contortion called a "composite outcome." Instead of measuring whether a drug slows biological decay, they would study if it simultaneously delays a cluster of separate, conventional illnesses—cancer, stroke, cognitive decline, and heart attack.

It’s a janky workaround. 

Science suggests that slowing the rate of biological aging can delay all these diseases at once. Yet researchers must bundle individual diagnoses together to give regulators a label they recognize.

When the FDA refuses to classify biological aging as an indication, it may discourage funding for root-cause preventative medicine.

It rewards the development of hyper-specialized, late-stage therapies to manage decline rather than preserving health.

Fixing this bottleneck means overhauling a bureaucratic playbook written in the 1960s. To turn our healthcare system from reactive damage control to prevention, the FDA must execute three reforms:

The science of longevity has arrived, but the regulatory framework isn’t welcoming it. Until the FDA rethinks its strategy, it’s easy to feel trapped in an expensive sick-care system that subsidizes decline, penalizes prevention, and waits for us to decay before lifting a finger.